{"success":true,"data":{"pressRelease":{"id":"31253","rtpr_id":"nPn6xLGpa","ticker":"HURA","exchange":"NASDAQ","all_tickers":["HURA"],"title":"TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference","author":"PR Newswire","published_at":"2026-05-12T11:30:00.802Z","article_body":"TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference\n\nPR Newswire\n\nTAMPA, Fla., May 12, 2026\n\nTAMPA, Fla., May 12, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc.\n(NASDAQ:HURA) (\"TuHURA\" or the \"Company\"), a Phase 3 immuno-oncology company\ndeveloping novel therapeutics to overcome resistance to cancer immunotherapy,\ntoday announced James A. Bianco, M.D., President and Chief Executive Officer\nof TuHURA, will participate in a fireside chat, at the 4th Annual H.C.\nWainwright BioConnect Investor Conference taking place in New York City.\n\n4(th) Annual H.C. Wainwright BioConnect Investor Conference\nDate: Tuesday, May 19, 2026\nTime: 2:00 pm ET\nLinks: To register and view presentation, click HERE\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4686286-1&h=2797783343&u=https%3A%2F%2Fjourney.ct.events%2Fview%2Ffc04fd46-c768-4000-bed0-2aea257bf12b&a=HERE)\n.\n\nA live and archived webcast of the presentation will also be available through\nthe investors page of TuHURA's corporate website at\nhttps://ir.tuhurabio.com/news-events/events\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4686286-1&h=4128602350&u=https%3A%2F%2Fir.tuhurabio.com%2Fnews-events%2Fevents&a=https%3A%2F%2Fir.tuhurabio.com%2Fnews-events%2Fevents)\n.\n\nAbout TuHURA Biosciences, Inc.\nTuHURA Biosciences, Inc. (Nasdaq: HURA) is a Phase 3 immuno-oncology company\ndeveloping novel technologies to overcome primary and acquired resistance to\ncancer immunotherapy, two of the most common reasons cancer immunotherapies\nfail to work or stop working in the majority of patients with cancer.\n\nTuHURA's lead innate immune agonist, IFx-2.0, is designed to overcome primary\nresistance to checkpoint inhibitors. TuHURA has initiated a single randomized\nplacebo-controlled Phase 3 registration trial of IFx-2.0 administered as an\nadjunctive therapy to Keytruda® (pembrolizumab) compared to Keytruda® plus\nplacebo in first-line treatment for advanced or metastatic Merkel Cell\nCarcinoma.\n\nIn addition to its innate immune agonist product candidates, TuHURA is\ndeveloping TBS-2025, a VISTA inhibiting mAb moving into Phase 1b/2 in mutNPM1\nr/r AML, a molecularly defined subgroup of patients with AML. In addition,\nTuHURA is leveraging its Delta Opioid Receptor technology to develop\nfirst-in-class, bi-specific, bi-functional antibody drug conjugates (ADCs)\ntargeting Myeloid Derived Suppressor Cells to inhibit their immune-suppressing\neffects on the tumor microenvironment to prevent T cell exhaustion and\nacquired resistance to checkpoint inhibitors and cellular therapies.\n\nFor more information, please visit www.tuhurabio.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4686286-1&h=738651174&u=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4608052-1%26h%3D4221218381%26u%3Dhttps%253A%252F%252Ftuhurabio.com%252F%26a%3Dwww.tuhurabio.com___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzozODlkNDA2NjQzMDliNmJjZjNmYjc4MzgxMDU3YTlhMDo3OmMxZGI6NjQ1NDIxNzIzN2JjMGFmNzVhMjlhNzYzYjU1NWY2ODAzY2NjZWQ5OTU5YTVhZmEwOGU4YjkyOWUwNTBjNTYxNTpwOlQ6Rg&a=www.tuhurabio.com)\n and connect with TuHURA on Facebook, X, and LinkedIn.\n\nInvestor Contact:\nMonique Kosse\nGilmartin Group\nMonique@GilmartinIR.com (mailto:Monique@GilmartinIR.com)\n\n(https://mma.prnewswire.com/media/2484202/TuHURA_Biosciences_Logo.html)\n\n \n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/tuhura-biosciences-to-present-at-the-4th-annual-hc-wainwright-bioconnect-investor-conference-302769078.html\n(https://www.prnewswire.com/news-releases/tuhura-biosciences-to-present-at-the-4th-annual-hc-wainwright-bioconnect-investor-conference-302769078.html)\n\nSOURCE TuHURA Biosciences, Inc.\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/2484202/TuHURA_Biosciences_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn6xLGpa","title":"TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference","author":"PR Newswire","ticker":"HURA","created":"2026-05-12T11:30:00.802Z","tickers":["HURA"],"exchange":"NASDAQ","article_body":"TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference\n\nPR Newswire\n\nTAMPA, Fla., May 12, 2026\n\nTAMPA, Fla., May 12, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc.\n(NASDAQ:HURA) (\"TuHURA\" or the \"Company\"), a Phase 3 immuno-oncology company\ndeveloping novel therapeutics to overcome resistance to cancer immunotherapy,\ntoday announced James A. Bianco, M.D., President and Chief Executive Officer\nof TuHURA, will participate in a fireside chat, at the 4th Annual H.C.\nWainwright BioConnect Investor Conference taking place in New York City.\n\n4(th) Annual H.C. Wainwright BioConnect Investor Conference\nDate: Tuesday, May 19, 2026\nTime: 2:00 pm ET\nLinks: To register and view presentation, click HERE\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4686286-1&h=2797783343&u=https%3A%2F%2Fjourney.ct.events%2Fview%2Ffc04fd46-c768-4000-bed0-2aea257bf12b&a=HERE)\n.\n\nA live and archived webcast of the presentation will also be available through\nthe investors page of TuHURA's corporate website at\nhttps://ir.tuhurabio.com/news-events/events\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4686286-1&h=4128602350&u=https%3A%2F%2Fir.tuhurabio.com%2Fnews-events%2Fevents&a=https%3A%2F%2Fir.tuhurabio.com%2Fnews-events%2Fevents)\n.\n\nAbout TuHURA Biosciences, Inc.\nTuHURA Biosciences, Inc. (Nasdaq: HURA) is a Phase 3 immuno-oncology company\ndeveloping novel technologies to overcome primary and acquired resistance to\ncancer immunotherapy, two of the most common reasons cancer immunotherapies\nfail to work or stop working in the majority of patients with cancer.\n\nTuHURA's lead innate immune agonist, IFx-2.0, is designed to overcome primary\nresistance to checkpoint inhibitors. TuHURA has initiated a single randomized\nplacebo-controlled Phase 3 registration trial of IFx-2.0 administered as an\nadjunctive therapy to Keytruda® (pembrolizumab) compared to Keytruda® plus\nplacebo in first-line treatment for advanced or metastatic Merkel Cell\nCarcinoma.\n\nIn addition to its innate immune agonist product candidates, TuHURA is\ndeveloping TBS-2025, a VISTA inhibiting mAb moving into Phase 1b/2 in mutNPM1\nr/r AML, a molecularly defined subgroup of patients with AML. In addition,\nTuHURA is leveraging its Delta Opioid Receptor technology to develop\nfirst-in-class, bi-specific, bi-functional antibody drug conjugates (ADCs)\ntargeting Myeloid Derived Suppressor Cells to inhibit their immune-suppressing\neffects on the tumor microenvironment to prevent T cell exhaustion and\nacquired resistance to checkpoint inhibitors and cellular therapies.\n\nFor more information, please visit www.tuhurabio.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4686286-1&h=738651174&u=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4608052-1%26h%3D4221218381%26u%3Dhttps%253A%252F%252Ftuhurabio.com%252F%26a%3Dwww.tuhurabio.com___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzozODlkNDA2NjQzMDliNmJjZjNmYjc4MzgxMDU3YTlhMDo3OmMxZGI6NjQ1NDIxNzIzN2JjMGFmNzVhMjlhNzYzYjU1NWY2ODAzY2NjZWQ5OTU5YTVhZmEwOGU4YjkyOWUwNTBjNTYxNTpwOlQ6Rg&a=www.tuhurabio.com)\n and connect with TuHURA on Facebook, X, and LinkedIn.\n\nInvestor Contact:\nMonique Kosse\nGilmartin Group\nMonique@GilmartinIR.com (mailto:Monique@GilmartinIR.com)\n\n(https://mma.prnewswire.com/media/2484202/TuHURA_Biosciences_Logo.html)\n\n \n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/tuhura-biosciences-to-present-at-the-4th-annual-hc-wainwright-bioconnect-investor-conference-302769078.html\n(https://www.prnewswire.com/news-releases/tuhura-biosciences-to-present-at-the-4th-annual-hc-wainwright-bioconnect-investor-conference-302769078.html)\n\nSOURCE TuHURA Biosciences, Inc.\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/2484202/TuHURA_Biosciences_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-05-12T11:30:00.839567901Z","server_sent_at_ms":1778585400839},"received_at":"2026-05-12T11:30:01.080Z","source_url":"https://www.prnewswire.com/news-releases/tuhura-biosciences-to-present-at-the-4th-annual-hc-wainwright-bioconnect-investor-conference-302769078.html"},"analysis":null,"durationMs":null,"modelName":null}}